Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 4/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | UBE2N | P61088 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17481396 | 0.87 | NPC1 (0.44) | CDK5CDK5R1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL16084216 | 0.85 | KCNQ2 (0.40) | CDK5CDK5R1KMT2ARORCSPR | |
| SCHEMBL19278031 | 0.84 | RORC (0.42) | MEN1KMT2ARORCSPRKCNQ2 | |
| SCHEMBL16084269 | 0.83 | RORC (0.41) | MEN1KMT2ARORCSPRKCNQ2 | |
| SCHEMBL16084170 | 0.83 | CYP11B2 (0.39) | KCNQ2 | |
| SCHEMBL16084166 | 0.82 | CYP11B2 (0.39) | CDK5CDK5R1SMN1; SMN2MAPK1KCNQ2 | |
| SCHEMBL19276239 | 0.81 | CYP11B2 (0.38) | ALK | |
| SCHEMBL16084331 | 0.81 | PDE4B (0.47) | SMN1; SMN2KCNQ2 | |
| SCHEMBL19278023 | 0.81 | CYP11B2 (0.39) | MAPK1GLAUBE2NNPSR1HSD17B10 | |
| SCHEMBL19278022 | 0.80 | CYP11B2 (0.38) | MAPK1ALKGLAUBE2NNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| EP-2970277-B1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-2970277-B1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2019-01-03 | — | — | US | disclosed |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2019-01-03 | — | — | US | disclosed |
| US-10106536-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-08-24 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650376-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-02-04 | — | — | US | disclosed |
| WO-2014145852-A2 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KNOPP BIOSCIENCES LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | CDK5 1026/4885CDK5R1 1402/4885SMN1; SMN2 286/4885 |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | CDK5 1026/4885CDK5R1 1402/4885SMN1; SMN2 286/4885 |
| US-10106536-B2 | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators | KCNA7, KCNA2, KCNK17 | CDK5 748/4885CDK5R1 630/4885SMN1; SMN2 1993/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | CDK5 1026/4885CDK5R1 1402/4885SMN1; SMN2 286/4885 |
| US-20160031875-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | CDK5 748/4885CDK5R1 630/4885SMN1; SMN2 1993/4885 |
| US-20190002464-A1 | IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | CDK5 894/4885CDK5R1 716/4885SMN1; SMN2 1979/4885 |
| US-20170240547-A1 | IMIDAZO(4,5-B) PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNA2, KCNK17 | CDK5 748/4885CDK5R1 630/4885SMN1; SMN2 1993/4885 |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | CDK5 1026/4885CDK5R1 1402/4885SMN1; SMN2 286/4885 |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | CDK5 1026/4885CDK5R1 1402/4885SMN1; SMN2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.